Search
MaxCyte Inc
MXCTAdd to Watchlist
1.215USD
-0.015-1.22%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
130.15MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.22%
5 Days
-4.33%
1 Month
-1.22%
6 Months
-21.61%
Year to Date
-21.61%
1 Year
-45.76%
Key Figures
1.250Open
1.275High
813.34KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.76%Turnover Ratio
1.230Prev. Close
1.190Low
567.45KTurnover
LossP/E Static
0.78P/B
0.00%Div Yield TTM
-18.43%ROA
2.40052wk High
0.40Volume Ratio
-41.05MNet Profit
107.12MShares
-0.3669EPS TTM
1.45Beta
-21.30%ROE
0.64352wk Low
6.91%Amplitude
73.22%Gross Margin
130.15MMarket Cap
0.61Reward/Risk
4.11%Risk Rate
TradingKey Stock Score of MaxCyte Inc
Currency: USD Updated: 2026-07-02Key Insights
MaxCyte Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 97 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.11.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MaxCyte Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
MaxCyte Inc Highlights
StrengthsRisks
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.03M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 33.03M.
Overvalued
The company’s latest PE is -3.31, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 79.92M shares, decreasing 19.15% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 3.29K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.80.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
4.107
Target Price
+231.25%
Upside Space
MaxCyte Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
MaxCyte Inc Info
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Ticker SymbolMXCT
CompanyMaxCyte Inc
CEOMasoud (Maher)
Websitehttps://www.maxcyte.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%Popular Instruments
53030.200
+187.700 (+0.35%)
29549.600
+238.200 (+0.81%)
7505.200
+33.700 (+0.45%)
15060.000
+257.000 (+1.74%)
69446.000
+1298.000 (+1.91%)
6380.400
+27.600 (+0.43%)
68.953
+0.609 (+0.89%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.620
+55.710 (+1.35%)
FAQs
What is the current price of MaxCyte Inc (MXCT)?
The current price of MaxCyte Inc (MXCT) is 1.22.
What is the symbol of MaxCyte Inc?
The ticker symbol of MaxCyte Inc is MXCT.
What is the 52-week high of MaxCyte Inc?
The 52-week high of MaxCyte Inc is 2.40.
What is the 52-week low of MaxCyte Inc?
The 52-week low of MaxCyte Inc is 0.64.
What is the market capitalization of MaxCyte Inc?
The market capitalization of MaxCyte Inc is 130.15M.
Is MaxCyte Inc (MXCT) currently rated as Buy, Hold, or Sell?
According to analysts, MaxCyte Inc (MXCT) has an overall rating of Buy, with a price target of 4.11.
What is the Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT)?
The Earnings Per Share (EPS TTM) of MaxCyte Inc (MXCT) is -0.42.